Pirtobrutinib in the BRUIN CLL-321 Study

Video content above is prompted by the following:

• During the 2024 American Society of Hematology annual meeting, the phase 3 BRUIN CLL-321 study looking at the noncovalent BTK inhibitor pirtobrutinib was presented. Provide a brief review of the methodology of the BRUIN CLL-321 study.
• What key takeaways from BRUIN CLL-321 suggest pirtobrutinib’s potential to address unmet needs in heavily pretreated relapsed/refractory CLL patients?
• How does the tolerability data from BRUIN CLL-321 inform strategies for managing adverse events in patients receiving pirtobrutinib?